Verona Pharma plc (Nasdaq: VRNA), a clinical-stage biopharmaceutical company dedicated to improving respiratory health, is pleased to announce its financial results for the first quarter of 2023 and to host a special investment community conference call on Tuesday, May 9th. At 9:00 a.m. EDT / 2:00 p.m. BST, join us to hear an update on the company’s progress as well as our financial results. We look forward to your participation in this exciting event!
About Verona Pharma
Verona Pharma is a clinical-stage biopharmaceutical company focused on developing innovative therapies to treat chronic respiratory diseases with significant unmet medical needs. Their product candidate, ensifentrine, has the potential to be the first therapy to combine bronchodilator and anti-inflammatory activity in one compound.
The Phase 3 clinical program ENHANCE (“Ensifentrine as a Novel inHAled Nebulized COPD thErapy”) has shown statistically significant and clinically meaningful improvements in lung function, and significantly reduced the rate and risk of COPD exacerbations.
Additionally, ensifentrine has potential applications in cystic fibrosis, asthma and other respiratory diseases. With the promise of a revolutionary treatment to help those suffering from respiratory diseases, Verona Pharma is continuing to develop ensifentrine for the betterment of patient care.